Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Should l Buy ?
Source: Benzinga
Analyst Ratings Overview: Intra-Cellular Therapies received mixed analyst ratings, with no bullish or bearish sentiments noted recently; the average 12-month price target has increased to $126.67, reflecting a positive shift in expectations.
Financial Performance Insights: The company reported significant revenue growth of approximately 51.49% over three months, but its net margin, return on equity, and return on assets are below industry averages, indicating challenges in profitability and asset management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
